# A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

> **NCT07198087** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Primary Central Nervous System Lymphoma (PCNSL)

## Interventions

- **DRUG:** Tirabrutinib

## Key facts

- **NCT ID:** NCT07198087
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2026-04-09
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07198087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07198087, "A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07198087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*